menu
    • menu
    [{"orgOrder":0,"company":"SNIPR Biome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"SNIPR001","moa":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"SNIPR Biome","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"SNIPR Biome \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"SNIPR Biome \/ Not Applicable"},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"SNIPR001","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SNIPR Biome","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"SNIPR Biome \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SNIPR Biome \/ Not Applicable"},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"SNIPR001","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SNIPR Biome","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"SNIPR Biome \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SNIPR Biome \/ Not Applicable"},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"SNIPR001","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SNIPR Biome","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"SNIPR Biome \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SNIPR Biome \/ Not Applicable"},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"SNIPR001","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SNIPR Biome","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"SNIPR Biome \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SNIPR Biome \/ Not Applicable"},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"SNIPR001","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SNIPR Biome","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"SNIPR Biome \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SNIPR Biome \/ Not Applicable"},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"CARB-X","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2024","type":"Funding","leadProduct":"SNIPR001","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SNIPR Biome","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"SNIPR Biome \/ CARB-X","highestDevelopmentStatusID":"6","companyTruncated":"SNIPR Biome \/ CARB-X"},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Gastroenterology","graph2":"Discovery","graph3":"SNIPR Biome","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"SNIPR Biome \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"SNIPR Biome \/ Bill & Melinda Gates Foundation"}]

    Find Clinical Drug Pipeline Developments & Deals by SNIPR Biome

    Menu

    SNIPR Biome

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            SNIPR Biome

                            Denmark arrow
                            Fi Europe 2024
                            Not Confirmed

                            SNIPR Biome

                            Denmark arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Gastroenterology

                            Study Phase : Discovery

                            Sponsor : Bill & Melinda Gates Foundation

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            SNIPR Biome Receives Funding for CRISPR-Medicines to Improve EED in Pregnant Women

                            Details : The funding from the Bill & Melinda Gates Foundation will be used to develop a microbiome-directed intervention designed to improve EED by reducing gut entero-pathogen burden in pregnant women.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            June 28, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Discovery

                            Sponsor : Bill & Melinda Gates Foundation

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            SNIPR Biome

                            Denmark arrow
                            Fi Europe 2024
                            Not Confirmed

                            SNIPR Biome

                            Denmark arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNIPR001

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : CARB-X

                            Deal Size : $5.4 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            SNIPR Biome Receives CARB-X Funding to Advance SNIPR001 in Haematological Cancers

                            Details : Funding supports SNIPR Biome’s CRISPR-medicine SNIPR001, undergoing early-stage trials for E. coli bloodstream infections in patients with hematological cancers.

                            Brand Name : SNIPR001

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 22, 2024

                            Lead Product(s) : SNIPR001

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : CARB-X

                            Deal Size : $5.4 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            SNIPR Biome

                            Denmark arrow
                            Fi Europe 2024
                            Not Confirmed

                            SNIPR Biome

                            Denmark arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNIPR001

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            SNIPR Biome Reports Positive Clinical Interim Results for Groundbreaking, First-in-Human, CRISPR-based Microbi...

                            Details : SNIPR001 is a novel, first-in-human, CRISPR-based microbial gene therapy, developed to specifically target and remove E. coli, including antibiotic-resistant strains, from the human gastrointestinal tract.

                            Brand Name : SNIPR001

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            May 31, 2023

                            Lead Product(s) : SNIPR001

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            SNIPR Biome

                            Denmark arrow
                            Fi Europe 2024
                            Not Confirmed

                            SNIPR Biome

                            Denmark arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNIPR001

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            SNIPR Biome Further Strengthens CRISPR/Cas IP Portfolio With Patent Grant

                            Details : SNIPR’s CRISPR technology provides a highly selective way to target individual bacterial strains for killing which can be useful for the prevention and treatment of any indication where a specific bacterial strain is the underlying cause of a disease.

                            Brand Name : SNIPR001

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            December 22, 2022

                            Lead Product(s) : SNIPR001

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            SNIPR Biome

                            Denmark arrow
                            Fi Europe 2024
                            Not Confirmed

                            SNIPR Biome

                            Denmark arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNIPR001

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            SNIPR Biome Launches A Non-Profit Patent Licensing Program To Enable The Field of CRISPR Editing in Prokaryote...

                            Details : SNIPR001, is the first orally dosed CRISPR-based therapeutic candidate and CRISPR-armed bacteriophage cocktail that targets antibiotic-resistant E. coli infections in hematological cancer patients.

                            Brand Name : SNIPR001

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            October 03, 2022

                            Lead Product(s) : SNIPR001

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            SNIPR Biome

                            Denmark arrow
                            Fi Europe 2024
                            Not Confirmed

                            SNIPR Biome

                            Denmark arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNIPR001

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            SNIPR Biome Granted New US Patent Covering Lytic CRISPR Phage

                            Details : SNIPR001, a CRISPR-armed bacteriophage cocktail that targets the prevention of antibiotic-resistant E. coli infections in hematological cancer patients.

                            Brand Name : SNIPR001

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            August 02, 2022

                            Lead Product(s) : SNIPR001

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            SNIPR Biome

                            Denmark arrow
                            Fi Europe 2024
                            Not Confirmed

                            SNIPR Biome

                            Denmark arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNIPR001

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            SNIPR BIOME Initiates First-in-Human Clinical Trial with SNIPR001

                            Details : The experimental CRISPR therapeutic, SNIPR001, is designed to selectively target and eradicate E. coli in the gut, thus preventing translocation of these bacteria to the bloodstream, in a high-risk population of hematological cancer patients at risk for ...

                            Brand Name : SNIPR001

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            April 20, 2022

                            Lead Product(s) : SNIPR001

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            SNIPR Biome

                            Denmark arrow
                            Fi Europe 2024
                            Not Confirmed

                            SNIPR Biome

                            Denmark arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNIPR001

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            SNIPR BIOME Announces FDA Clearance of Investigational New Drug (IND) Application for SNIPR001, a Novel CRISPR...

                            Details : INDA approval is based on the positive pre-clinical data for SNIPR001 which showed that it holds a huge potential against life-threatening infections and also in modulating microbiome-associated diseases.

                            Brand Name : SNIPR001

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            January 11, 2022

                            Lead Product(s) : SNIPR001

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth